• Feb 20, 2025

Sabre (NASDAQ:SABR) Posts Q4 Sales In Line With Estimates

Travel technology company Sabre (NASDAQ:SABR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4% year on year to $714.7 million. Its non-GAAP loss of $0.08 per share was 22% above analysts’ consensus estimates.

  • Feb 20, 2025

Unity’s (NYSE:U) Q4: Beats On Revenue But Stock Drops

Game engine maker Unity (NYSE:U) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales fell by 25% year on year to $457.1 million. On the other hand, next quarter’s revenue guidance of $410 million was less impressive, coming in 5.6% below analysts’ estimates. Its GAAP loss of $0.30 per share was 18.6% above analysts’ consensus estimates.

  • Feb 20, 2025

Shyft (NASDAQ:SHYF) Misses Q4 Sales Targets

Vehicle manufacturer Shyft (NASDAQ:SHYF) fell short of the market’s revenue expectations in Q4 CY2024, with sales flat year on year at $201.4 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $920 million at the midpoint. Its non-GAAP profit of $0.15 per share was 18.4% above analysts’ consensus estimates.

  • Feb 20, 2025

Walmart-backed PhonePe prepares for Indian stock market debut

Walmart-backed Indian fintech firm PhonePe is beginning preparatory steps for a public listing on the country's stock exchanges, the company said on Thursday. "PhonePe's strong top-line and bottom-line growth across its diverse business portfolio, as detailed in its FY23-24 annual report, makes this a suitable time to prepare for a public listing," the company said in a statement. The Indian stock market saw a significant upswing for much of 2024, with many companies launching their IPOs, but a downturn since October has weighed on investor sentiment.

  • Feb 20, 2025

Leonardo DRS (NASDAQ:DRS) Posts Better-Than-Expected Sales In Q4, Full-Year Sales Guidance is Optimistic

Aerospace and defense company Leonardo DRS (NASDAQ:DRS) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 5.9% year on year to $981 million. The company’s full-year revenue guidance of $3.48 billion at the midpoint came in 1.6% above analysts’ estimates. Its non-GAAP profit of $0.38 per share was 7.6% above analysts’ consensus estimates.

  • Feb 20, 2025

Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $167.5 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $697.5 million at the midpoint. Its non-GAAP profit of $0.44 per share was 7.9% above analysts’ consensus estimates.